VGX Pharmaceuticals and Dowpharma contract manufacturing services, a business unit of The Dow Chemical Co., have signed an R&D Agreement to advance the development of VGX-100, VGX’s novel cancer compound in preclinical development. Under the terms of the agreement, Dowpharma will perform a feasibility study for the expression of VGX-100 using its Pfenex Expression Technology. Pfenex Expression Technology accelerates speed to market for vaccines and biotherapeutics by improving quality,...